Alterity Therapeutics Completes Final Patient Visit in ATH434-202 Phase 2 Trial.

Alterity Therapeutics (ASX: ATH) has announced the completion of the last patient visit in its ATH434-202 open-label Phase 2 trial for multiple system atrophy (MSA). The study evaluates the safety, efficacy, and biomarker effects of ATH434, a disease-modifying drug candidate for Parkinsonian disorders. The trial enrolled 10 individuals with advanced MSA, administering ATH434 for 12 months to assess its impact on brain volume, iron levels, and α-synuclein aggregation. 

Following positive results from its randomized, double-blind Phase 2 trial, Alterity’s open-label study aims to further understand ATH434’s therapeutic potential. The company expects to release topline data by mid-2025. ATH434 has received Orphan Drug Designation from the U.S. FDA and European Commission. This milestone strengthens Alterity’s commitment to developing treatments for neurodegenerative diseases. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com